Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals, Inc. (AMRX) reported insider activity by its Executive Vice President. On November 12, 2025, the officer exercised stock options for 36,331 and 95,525 shares at an exercise price of $2.75 per share and sold 131,856 Class A shares at a $11.92 weighted average price.
The sale occurred across multiple trades between $11.85 and $12.02 per share. Following these transactions, the reporting person directly beneficially owned 146,403 shares. The reported option grants (fully vested) show 0 derivative securities remaining after exercise, with prior expirations listed as May 7, 2028 and March 1, 2029.
Amneal Pharmaceuticals (AMRX) reported Q3 2025 results. Net revenue was $784.5 million, up from $702.5 million a year ago. Operating income was $70.3 million versus $88.8 million. Net income attributable to Amneal was $2.4 million, or $0.01 per diluted share.
Performance by segment in Q3: Affordable Medicines $460.7 million, Specialty $125.2 million, and AvKARE $198.5 million. Year to date, net revenue reached $2.20 billion and operating income was $282.1 million, with diluted EPS of $0.11.
Results reflect a $31.4 million loss on refinancing, a $22.8 million intangible asset impairment tied to an FDA complete response letter dated July 22, 2025, and a tax benefit from the One Big Beautiful Bill Act that reduced current income tax liabilities by $23.5 million in Q3. Cash from operating activities for the first nine months was $209.7 million, with cash and cash equivalents of $201.2 million at September 30, 2025. Long‑term debt, net, was $2.57 billion.
Amneal Pharmaceuticals (AMRX) furnished an 8‑K announcing it issued a press release for its third quarter ended September 30, 2025. The information was provided under Item 2.02 and Item 7.01 and is being treated as furnished, not filed.
Amneal will host a conference call and live webcast at 8:30 a.m. Eastern Time on October 30, 2025. Access the webcast via the Investor Relations site at https://investors.amneal.com or join by phone at (833) 470‑1428 (U.S.) with access code 272787. A replay will be posted after the call, with international dial-in options available at the provided NetRoadshow link.
Amneal Pharmaceuticals, Inc. reporting person Chintu Patel amended a Schedule 13D to disclose ownership of 25,910,032 shares of Class A common stock, representing 8.2% of the outstanding Class A shares based on 314,079,309 shares outstanding. On October 3, 2025 Mr. Patel caused a trust he controls to contribute 13,257,287 shares to Shivkan Holdings X, LLC, the Trust's wholly owned LLC. Shivkan then entered a margin loan with Citibank, pledging those 13,257,287 shares as collateral under a Pledge and Security Agreement; the loan matures on April 5, 2027. The filing notes Citibank may foreclose and dispose of the pledged shares upon customary events, and an Issuer Letter Agreement was entered to facilitate Citibank's rights.
Amneal Pharmaceuticals, Inc. Schedule 13D/A shows that Dipan Patel beneficially owns 23,828,992 shares of Class A common stock, representing 7.6% of the 314,079,309 shares outstanding used for the calculation. The filing states these shares are held of record by trusts controlled by the reporting person and that Patel has sole voting and dispositive power over the shares.
The amendment adds loan documentation: a trust controlled by Patel pledged 3,050,000 Class A shares as collateral under a promissory note and related agreements with Enterprise Bank & Trust. The loan matures on 11/05/2026, and customary foreclosure rights exist for the bank if events of default occur.
Amneal Pharmaceuticals director John Kiely reported a sale of Class A common stock on 08/27/2025. The Form 4 shows 32,000 shares were sold at a weighted-average price of $9.23 per share (prices ranged $9.20–$9.25). After the sale, the reporting person beneficially owned 225,433 shares, held directly. The filing was signed by an attorney-in-fact on 08/28/2025. The Form 4 discloses the transaction details and the footnote states the seller will provide a breakdown of shares sold at each price upon request.
Amneal Pharmaceuticals (AMRX) filed a Form 144 to notify a proposed sale of 32,000 Class A shares through Merrill Lynch (157 Church St, New Haven, CT) with an approximate sale date of 08/27/2025. The filing reports an aggregate market value of $293,810 for the shares and shows 314,079,309 shares outstanding for the class. The shares were acquired on 05/10/2024 as equity compensation from Amneal Pharmaceuticals, with payment recorded on the same date. The filer reports no sales in the past three months and provides the standard certification that no undisclosed material adverse information is known.
Insider sales by Amneal Pharmaceuticals officer. Nikita Shah, identified as Executive Vice President and reporting person, sold a total of 120,832 shares of Amneal Pharmaceuticals, Inc. (AMRX) in two transactions: 114,492 shares on 08/22/2025 at a weighted-average price of $9.66 and 6,340 shares on 08/25/2025 at a weighted-average price of $9.50. Following these disposals the filing shows beneficial ownership of 146,403 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025. The filing provides weighted-price ranges for the sales and offers to provide detailed per-transaction quantities on request.
Andrew S. Boyer, Executive Vice President of Amneal Pharmaceuticals (AMRX), reported insider transactions executed on 08/20/2025. He exercised 175,000 stock options at a $2.75 exercise price, acquiring 175,000 Class A common shares. On the same date he sold 279,244 Class A common shares at a weighted average price of $9.38, with sale prices ranging from $9.30 to $9.40 per share.
After these transactions the Form 4 shows Mr. Boyer beneficially owned 431,670 Class A shares before the sale line and 152,426 Class A shares following the sale line, and held 97,480 options (derivative securities) after the reported option exercise. The filing was signed by an attorney-in-fact on 08/22/2025 and notes the exercised options were fully vested.
Amneal Pharmaceuticals (AMRX) Form 144 notice records a proposed sale of 36,796 Class A shares with an aggregate market value of $356,921, intended for sale on 08/22/2025 on NASDAQ. The filer reports the shares were acquired as equity compensation from Amneal Pharmaceuticals on 03/01/2023 (18,628 shares) and 03/03/2023 (18,168 shares). The filing also discloses three recent sales by the same person during August 2025 totaling 205,730 Class A shares for gross proceeds of $1,935, - [aggregate per rows: $818,930; $663,065; $453,000]. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and carries the required signature and warning about false statements.